ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 327

Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis

Katherine D. Wysham1, Dolores M. Shoback2, Kashif Jafri1, Sarah L. Patterson3, Gabriela Schmajuk4, John B. Imboden Jr.5 and Patricia P. Katz5, 1University of California, San Francisco, San Francisco, CA, 2Medicine, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, 3Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 4San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, 5Medicine, University of California, San Francisco, San Francisco, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ACPA, Osteoporosis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:   Osteoporotic fractures are associated with high morbidity and mortality. Persons with rheumatoid arthritis (RA) have twice the risk of osteoporosis-related fracture than age-matched controls. It is not known, however, which characteristics of RA or its treatments have the greatest impact on bone mineral density (BMD). We investigated associations of RA characteristics, medication use, and body composition to low BMD in patients with RA.

Methods: We performed a cross-sectional analysis of an existing longitudinal RA cohort study from years 2007-2009. All patients met ACR classification criteria for RA. Demographic, clinical, laboratory and functional variables were collected at study visits. Body composition (fat, lean muscle and BMD) was measured by dual x-ray absorptiometry. We used linear regression to evaluate the association between predictors and femoral neck BMD. To identify independent predictors of BMD, we performed multivariable linear regression analyses that included variables significant in the univariable analyses at p<0.10. To determine if there was a linear trend between anti-cyclic citrullinated peptide (CCP) level and BMD, we repeated the linear regression analysis restricted to anti-CCP positive participants.

Results: Of the 138 participants (82 women, 56 men), 70% were rheumatoid factor positive, and 55% were anti-CCP positive to a level 3 times the upper limit of normal. Mean disease duration was 19±10.9 years. 44% of participants reported taking prednisone and of those taking prednisone, the mean dose was 7.1±6.1 mg/day. The mean body mass index (BMI) was 27.2±6.0 kg/m2, and mean appendicular lean mass index (ALMI) was 6.4±1.2 kg/m2; 59% of the participants were obese based on percent total body fat. 52% had low BMD based on a T or Z score <=-1 and 27% reported taking osteoporosis medications. Age and anti-CCP positivity were negatively associated with BMD, even after controlling for other variables (β=-0.003 and -0.055, respectively, p<0.05) (Table). ALMI had an independent positive association with BMD (β=0.053, p <0.0001). Among anti-CCP positive participants (n=61), higher anti-CCP level was associated with lower BMD (β for each 20-unit increase in anti-CCP=-0.011, p=0.026) when controlling for age, sex, disease duration, ALMI and knee flexion strength.

Conclusion: Anti-CCP positivity, ALMI and age were independently associated with BMD in patients with RA. The linear relationship of anti-CCP levels with lower BMD supports the hypothesis that processes specific to RA negatively impact BMD. In contrast, ALMI was positively associated with BMD, emphasizing the role of muscle mass as a potentially modifiable risk factor. Our findings highlight the complicated interplay of RA disease-specific and functional factors and their impact on bone mass.


Disclosure: K. D. Wysham, None; D. M. Shoback, None; K. Jafri, None; S. L. Patterson, None; G. Schmajuk, None; J. B. Imboden Jr., None; P. P. Katz, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Wysham KD, Shoback DM, Jafri K, Patterson SL, Schmajuk G, Imboden JB Jr., Katz PP. Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/association-of-anti-cyclic-citrullinated-peptide-seropositivity-and-lean-mass-index-with-low-bone-mineral-density-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-anti-cyclic-citrullinated-peptide-seropositivity-and-lean-mass-index-with-low-bone-mineral-density-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology